ImmunityBio (IBRX) Revenue & Revenue Breakdown
ImmunityBio Revenue Highlights
Latest Revenue (Y)
$622.00K
Latest Revenue (Q)
$1.05M
Main Geography (Y)
Europe
ImmunityBio Revenue by Period
ImmunityBio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $622.00K | 159.17% |
| 2022-12-31 | $240.00K | -74.30% |
| 2021-12-31 | $934.00K | 54.38% |
| 2020-12-31 | $605.00K | -72.52% |
| 2019-12-31 | $2.20M | 4585.11% |
| 2018-12-31 | $47.00K | 4.44% |
| 2017-12-31 | $45.00K | 2.27% |
| 2016-12-31 | $44.00K | -81.36% |
| 2015-12-31 | $236.00K | -63.18% |
| 2014-12-31 | $641.00K | - |
ImmunityBio generated $622.00K in revenue during NA 2023, up 159.17% compared to the previous quarter, and up 1323.40% compared to the same period a year ago.
ImmunityBio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.05M | 2517.50% |
| 2024-03-31 | $40.00K | -71.22% |
| 2023-12-31 | $139.00K | 69.51% |
| 2023-09-30 | $82.00K | 100.00% |
| 2023-06-30 | $41.00K | -88.61% |
| 2023-03-31 | $360.00K | 393.15% |
| 2022-12-31 | $73.00K | -38.14% |
| 2022-09-30 | $118.00K | 237.14% |
| 2022-06-30 | $35.00K | 150.00% |
| 2022-03-31 | $14.00K | -96.41% |
| 2021-12-31 | $390.00K | 490.91% |
| 2021-09-30 | $66.00K | -80.53% |
| 2021-06-30 | $339.00K | 143.88% |
| 2021-03-31 | $139.00K | -194.56% |
| 2020-12-31 | $-147.00K | -197.35% |
| 2020-09-30 | $151.00K | -65.37% |
| 2020-06-30 | $436.00K | 164.24% |
| 2020-03-31 | $165.00K | -82.07% |
| 2019-12-31 | $920.00K | 7566.67% |
| 2019-09-30 | $12.00K | -29.41% |
| 2019-06-30 | $17.00K | 240.00% |
| 2019-03-31 | $5.00K | -28.57% |
| 2018-12-31 | $7.00K | -77.42% |
| 2018-09-30 | $31.00K | 675.00% |
| 2018-06-30 | $4.00K | -20.00% |
| 2018-03-31 | $5.00K | -58.33% |
| 2017-12-31 | $12.00K | 50.00% |
| 2017-09-30 | $8.00K | -42.86% |
| 2017-06-30 | $14.00K | 27.27% |
| 2017-03-31 | $11.00K | -21.43% |
| 2016-12-31 | $14.00K | 16.67% |
| 2016-09-30 | $12.00K | - |
| 2016-06-30 | $12.00K | 100.00% |
| 2016-03-31 | $6.00K | -57.14% |
| 2015-12-31 | $14.00K | 40.00% |
| 2015-09-30 | $10.00K | -89.01% |
| 2015-06-30 | $91.00K | - |
ImmunityBio generated $1.05M in revenue during Q2 2024, up 2517.50% compared to the previous quarter, and up 290.83% compared to the same period a year ago.
ImmunityBio Revenue Breakdown
ImmunityBio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| UNITED STATES | $31.00K | $42.00K | $373.00K |
| Europe | $591.00K | $198.00K | $561.00K |
ImmunityBio's latest annual revenue breakdown by geography, as of Dec 23: Europe (95.02%), and UNITED STATES (4.98%).
Quarterly Revenue by Country
| Country | Mar 18 |
|---|---|
| San Diego California | $100.00K |
ImmunityBio's latest quarterly revenue breakdown by geography, as of Mar 18: San Diego California (100.00%).
ImmunityBio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| MCRB | Seres Therapeutics | $126.33M | - |
| ARDX | Ardelyx | $124.46M | $73.22M |
| VIR | Vir Bio | $86.18M | $3.08M |
| CVAC | CureVac | $52.70M | $12.37M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| LXRX | Lexicon Pharmaceuticals | $1.20M | $1.65M |
| IBRX | ImmunityBio | $622.00K | $1.05M |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| ELEV | Elevation Oncology | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| EFTR | eFFECTOR Therapeutics | - | - |
IBRX Revenue FAQ
What is ImmunityBio’s yearly revenue?
ImmunityBio's yearly revenue for 2023 was $622K, representing an increase of 159.17% compared to 2022. The company's yearly revenue for 2022 was $240K, representing a decrease of -74.30% compared to 2021. IBRX's yearly revenue for 2021 was $934K, representing an increase of 54.38% compared to 2020.
What is ImmunityBio’s quarterly revenue?
ImmunityBio's quarterly revenue for Q2 2024 was $1.05M, a 2517.50% increase from the previous quarter (Q1 2024), and a 2453.66% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $40K, a -71.22% decrease from the previous quarter (Q4 2023), and a -88.89% decrease year-over-year (Q1 2023). IBRX's quarterly revenue for Q4 2023 was $139K, a 69.51% increase from the previous quarter (Q3 2023), and a 90.41% increase year-over-year (Q4 2022).
What is ImmunityBio’s revenue growth rate?
ImmunityBio's revenue growth rate for the last 3 years (2021-2023) was -33.40%, and for the last 5 years (2019-2023) was -71.75%.